About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
M
MD Anderson 2020 Update on IO for Metastatic Melanoma: What Is the 5-Year OS With Single-Agent PD-1 & PD-/CTLA-4 Agents? Which Options to Consider After Progression on PD-1(+/- Ipi)?
By
MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
FEATURING
Michael Davies
By
MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
FEATURING
Michael Davies
242 views
November 19, 2020
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
10:01
AAD 2024 Insights
AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma
Feat.
V. Sondak
12:46
Stanford Medicine
FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …
Feat.
A. Betof Warner
17:50
AdventHealth
Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…
Feat.
G. Sonpavde
23:09
Total Health
Key Updates in Skin Melanoma
Feat.
R. Seedor
06:39
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Final Analysis of Distant Metastasis-Free…
Feat.
J. Luke
24:14
Masterclasses in Dermatology
Advances in the Treatment of Melanoma
Feat.
D. Fisher
17:39
Melanoma Bridge 2023
Major Emerging Paradigm Shifts That Will Change Melanoma Management …
Feat.
A. Eggermont
10:39
University of Colorado Department of Medicine
Cardio-Oncology: Definitions and Scope
Feat.
L. Kondapalli
08:38
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Phase 3 Trial Comparing Fianlimab + Cem…
Feat.
T. Panella
19:52
OncoAlert
Melanoma Updates: Adjuvant Therapy, Advanced Disease, Uveal Melanoma…
Feat.
A. Betof Warner
52:19
Winship Melanoma and Cutaneous Oncology Symposium
2024 Updates on Neoadjuvant Therapy for Resectable Melanoma
Feat.
S. Patel
08:46
Sapna Patel
Neoadjuvant Immunotherapy in the Treatment of Melanoma: What Do We K…
08:27
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Significant Durable Response With Fianlim…
Feat.
O. Hamid
18:21
Vanderbilt University Medical Center (VUMC)
NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…
Feat.
D. Johnson
30:29
NYU Langone
Updates in Treatment with Immunotherapy for Melanoma and Related Mal…
Feat.
J. Weber
25:10
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024
Immunotherapy Combinations in Melanoma in 2024
Feat.
J. Moyers
20:55
2023 West Oncology Conference
2023 West Oncology Conference: Melanoma Updates
Feat.
M. Mooradian
04:45
Sapna Patel
Optimal Duration of Neoadjuvant Treatment in Melanoma: What We Do No…
20:32
Melanoma Bridge 2023
Targeted Therapy in BRAF-Mutated Metastatic Melanoma
Feat.
R. Dummer
14:36
Melanoma Bridge 2023
Treating PD-1 Refractory Melanoma With TIL Therapy vs. Nivo+Ipi: Pro…
Feat.
J. Smithy
